Form 4: Director B. Lynne Parshall Sells Ionis Pharmaceuticals Stock

Ionis Pharmaceuticals Director B. Lynne Parshall sold 5,000 shares of common stock via a pre-arranged Rule 10b5-1 trading plan.

Summary

• Director B. Lynne Parshall sold a total of 5,000 shares of Ionis Pharmaceuticals (IONS) common stock on April 15, 2026.
• The sales were executed in two tranches: 4,466 shares at a weighted average price of $76.19 and 534 shares at a weighted average price of $76.97.
• Following these transactions, the reporting person retains beneficial ownership of 51,344 shares of common stock.
• The transactions were conducted pursuant to a Rule 10b5-1 trading plan adopted on May 6, 2025.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was conducted through a pre-planned, automated trading program rather than an opportunistic market move.

Positives

• The sale was executed under a pre-established Rule 10b5-1 trading plan, which is a standard mechanism for insiders to sell stock without concerns regarding non-public information.

Negatives

• The sale represents a reduction in the equity stake held by a member of the Board of Directors.

Risks

• Insider selling can sometimes be perceived negatively by retail investors as a signal of management sentiment regarding future stock performance.

Future Outlook

No forward-looking guidance regarding company operations or financial performance was provided in this filing.

Industry Context

StockSavvy.ai notes that insider sales executed under Rule 10b5-1 plans are common in the biotechnology sector, where executives and directors frequently utilize these plans for liquidity and diversification purposes.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is the industry standard for corporate insiders to manage equity holdings while maintaining compliance with SEC regulations.

Stakeholder Impact

• Minimal impact on shareholders as the sale was pre-planned and represents a small portion of the director's total holdings.

Next Steps

• No future actions or milestones were disclosed in this filing.

Key Dates

Keywords

Ionis Pharmaceuticals, IONS, Insider Trading, Form 4, Biotech, B. Lynne Parshall